Standout Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell C... 1996 2026 2006 2016 4.4k
  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma (2007)
    Robert J. Motzer, Thomas E. Hutson et al. New England Journal of Medicine
  2. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma (2007)
    Gary R. Hudes, Michael A. Carducci et al. New England Journal of Medicine
  3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008)
    Robert J. Motzer, Bernard Escudier et al. The Lancet
  4. Renal-Cell Carcinoma (1996)
    Robert J. Motzer, Neil H. Bander et al. New England Journal of Medicine
  5. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009)
    Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology
  6. Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma (1999)
    Robert J. Motzer, Madhu Mazumdar et al. Journal of Clinical Oncology
  7. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma (2005)
    Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology
  8. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma (2002)
    Robert J. Motzer, Jennifer Bacik et al. Journal of Clinical Oncology
  9. Sunitinib in Patients With Metastatic Renal Cell Carcinoma (2006)
    Robert J. Motzer, Brian I. Rini et al. JAMA
  10. Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010)
    Robert J. Motzer, Bernard Escudier et al. Cancer
  11. Systemic Therapy for Metastatic Renal-Cell Carcinoma (2017)
    Toni K. Choueiri, Robert J. Motzer New England Journal of Medicine
  12. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (2014)
    Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology
  13. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (2015)
    Robert J. Motzer, Thomas E. Hutson et al. The Lancet Oncology
  14. Testicular Germ-Cell Cancer (1997)
    George J. Bosl, Robert J. Motzer New England Journal of Medicine
  15. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma (2004)
    Robert J. Motzer, Jennifer Bacik et al. Journal of Clinical Oncology
  16. A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA (2001)
    Michael W. Kattan, Victor E. Reuter et al. The Journal of Urology
  17. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (2013)
    Robert J. Motzer, Bernard Escudier et al. The Lancet Oncology
  18. Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011)
    Brian I. Rini, Dongrui R. Lu et al. JNCI Journal of the National Cancer Institute
  19. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020)
    Laurence Albigès, Nizar M. Tannir et al. ESMO Open
  20. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors (2020)
    Matthew H. Taylor, Chung‐Han Lee et al. Journal of Clinical Oncology
  21. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (2022)
    Robert J. Motzer, Thomas Powles et al. The Lancet Oncology
  22. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma (2023)
    Toni K. Choueiri, Thomas Powles et al. New England Journal of Medicine

Immediate Impact

23 by Nobel laureates 17 from Science/Nature 152 standout
Sub-graph 1 of 15

Citing Papers

Renal Cell Carcinoma
2024 Standout
Renal cell carcinoma
2024 Standout
56 intermediate papers

Works of Robert J. Motzer being referenced

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
2018
and 83 more

Author Peers

Author Last Decade Papers Cites
Robert J. Motzer 38543 30079 17413 19079 921 57.3k
Ronald M. Bukowski 19691 17507 10156 13215 454 33.5k
Toni K. Choueiri 24081 14617 10353 17579 1.2k 40.4k
Eric Van Cutsem 35069 15711 12134 68215 1.2k 92.5k
Bernard Escudier 26197 22473 13763 14176 712 40.8k
Robert A. Figlin 25082 21802 11895 11928 467 37.4k
Josep Tabernero 14187 14088 8631 33324 1.1k 49.1k
Nicholas J. Vogelzang 22117 8203 6308 16878 693 40.8k
W. Marston Linehan 21208 22532 13176 7535 581 44.8k
Brian I. Rini 25164 19308 12675 15310 761 37.4k
Frances A. Shepherd 32265 11958 7188 30783 662 48.5k

All Works

Loading papers...

Rankless by CCL
2026